ID: ALA1761321

Max Phase: Preclinical

Molecular Formula: C21H26F3N3O2S

Molecular Weight: 441.52

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCS(=O)(=O)CC12CCC(c3nnc(-c4ccccc4C(F)(F)F)n3C)(CC1)CC2

Standard InChI:  InChI=1S/C21H26F3N3O2S/c1-3-30(28,29)14-19-8-11-20(12-9-19,13-10-19)18-26-25-17(27(18)2)15-6-4-5-7-16(15)21(22,23)24/h4-7H,3,8-14H2,1-2H3

Standard InChI Key:  IIUAOVVCEISVLV-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 441.52

Molecular Weight (Monoisotopic): 441.1698

AlogP: 4.53

#Rotatable Bonds: 5

Polar Surface Area: 64.85

Molecular Species: NEUTRAL

HBA: 5

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 2.24

CX LogP: 3.53

CX LogD: 3.53

Aromatic Rings: 2

Heavy Atoms: 30

QED Weighted: 0.68

Np Likeness Score: -0.80

References

1. Maletic M, Leeman A, Szymonifka M, Mundt SS, Zokian HJ, Shah K, Dragovic J, Lyons K, Thieringer R, Vosatka AH, Balkovec J, Waddell ST..  (2011)  Bicyclo[2.2.2]octyltriazole inhibitors of 11β-hydoxysteroid dehydrogenase type 1. Pharmacological agents for the treatment of metabolic syndrome.,  21  (8): [PMID:21421311] [10.1016/j.bmcl.2011.01.018]

2. Bauman DR, Whitehead A, Contino LC, Cui J, Garcia-Calvo M, Gu X, Kevin N, Ma X, Pai LY, Shah K, Shen X, Stribling S, Zokian HJ, Metzger J, Shevell DE, Waddell ST..  (2013)  Evaluation of selective inhibitors of 11β-HSD1 for the treatment of hypertension.,  23  (12): [PMID:23659858] [10.1016/j.bmcl.2013.03.011]

Source

Source(1):

• Scientific Literature